(Q44044770)

29 November 2017

title

Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma (English)

1 reference

29 November 2017

5

Champlin R

1 reference

29 November 2017

6

Giralt S

1 reference

29 November 2017

Alexanian R

1

1 reference

29 November 2017

Weber D

series ordinal

2

1 reference

29 November 2017

Delasalle K

series ordinal

3

1 reference

29 November 2017

Handy B

series ordinal

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Bone Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

34

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

229-234

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

Autologous stem cell transplantation for relapsed and primary refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704562

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704562

1 reference

29 November 2017

1 reference